Health-Related Quality of Life Subdomains in Patients with Parkinson’s Disease: The Role of Gender
Table 1
Summary of study sample characteristics and gender comparisons ().
Max. score
M (SD) range
Total ()
Women ()
Men ()
Age
—
69.64 (8.43)
70.16 (7.42)
69.34 (8.99)
0.955b
41–86
47–86
41–83
PDQ-39
100
26.23 (15.08)
26.97 (14.32)
25.79 (15.54)
0.341b
0–79.95
0–79.95
1.67–67.61
PDQ-39 physical-functioninga
100
31.80 (20.17)
33.61 (19.34)
30.73 (20.63)
0.154b
0–86.94
0–79.17
0–86.94
PDQ-39 cognitiona
100
26.62 (17.66)
22.77 (15.70)
28.90 (18.40)
0.017b
0–83.34
0–66.66
0–83.34
PDQ-39 socioemotionala
100
20.36 (15.40)
23.02 (16.01)
18.79 (14.85)
0.032b
0–89.58
0–89.58
0–56.25
PANDA
30
24.82 (3.57)
25.60 (3.09)
24.36 (3.76)
0.020b
14–30
17–30
14–30
BDI-II
63
12.10 (7.80)
13.03 (7.67)
11.55 (7.84)
0.090b
0–38
0–37
0–38
NMSS
360
57.31 (31.76)
55.62 (26.15)
58.32 (34.69)
0.987b
6–198
8–122
6–198
UPDRS-III
108
28.09 (8.94)
26.87 (8.36)
28.81 (9.21)
0.087b
9–65
11–51
9–65
Disease duration
—
5.88 (5.73)
6.20 (5.76)
5.69 (5.72)
0.426b
0: 25
0: 23
0: 25
H&Y
5
1: 29
1: 11
1: 18
0.563c
2: 87
2: 34
2: 53
3: 106
3: 35
3: 71
4: 23
4: 11
4: 12
LEDD
—
610.07 (408.29)
580.94 (433.05)
627.28 (393.36)
0.204b
0–2065
0–2065
0–1780
Note. Significant gender comparisons appear in bold. BDI-II = Beck’s Depression Inventory II; H&Y = Hoehn and Yahr stage; LEDD = levodopa equivalent daily dose; NMSS = Nonmotor Symptom Scale; PANDA = Parkinson Neuropsychometric Dementia Assessment; PDQ-39 = Parkinson’s Disease Questionnaire 39; UPDRS-III = Unified Parkinson’s Disease Rating Scale Part III. aFor a detailed description of PDQ-39 physical-functioning, cognition, and socioemotional component scores, see principal component analysis; bcomparison between women and men with the Mann–Whitney U test; ccomparison between women and men with the chi-square test.
